Showing results (51-60 of 72) with videos related to
Sort By:
Pageof 8
Frontiers in Neurology|July 19, 2021
Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [ F]PI-2620Marie Willroider, Sigrun Roeber, Anja K E Horn, et al.European Journal of Nuclear Medicine and Molecular Imaging|July 3, 2019
Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathiesHeiko Kroth, Felix Oden, Jerome Molette, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 27, 2014
First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinomaIrene A Burger, Sabine Zitzmann-Kolbe, Jan Pruim, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 7, 2017
Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic studyMathieu Ceccaldi, Thérèse Jonveaux, Antoine Verger, et al.Movement Disorders : Official Journal of the Movement Disorder Society|July 18, 2024
Neuroinflammation Parallels 18F-PI-2620 Positron Emission Tomography Patterns in Primary 4-Repeat TauopathiesMaura Malpetti, Sebastian N Roemer, Stefanie Harris, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 4, 2024
Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [18F]PI-2620Gérard N Bischof, Matthias Brendel, Henryk Barthel, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2024
Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management StudyLyduine E Collij, Gérard N Bischof, Daniele Altomare, et al.JAMA Neurology|June 12, 2018
Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE ProjectArno de Wilde, Wiesje M van der Flier, Wiesje Pelkmans, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studiesTimothy A Yap, Hendrik-Tobias Arkenau, D Ross Camidge, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 20, 2018
AMYPAD Diagnostic and Patient Management Study: Rationale and designGiovanni B Frisoni, Frederik Barkhof, Daniele Altomare, et al.Pageof 8